Description of 3 cases in Vietnam of aspirin desensitization in patients with coronary artery disease and coexisting aspirin hypersensitivity

Dinh Van Nguyen, Hieu Chu Chi, Doan Van Nguyen, Timothy J. Craig, Sheryl Van Nunen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aspirin (ASA) hypersensitivity comprises types I to III (Cox-1 mediated) and types IV and V (IgE antibody mediated). Rapid, low-dose (81-325 mg/day) ASA desensitization regimens are known to be useful in establishing ASA tolerance in patients with coronary artery disease and coexisting ASA/nonsteroidal anti-inflammatory drug hypersensitivity. We document 3 cases in Vietnam of desensitization to ASA in patients with coronary artery disease and coexisting ASA hypersensitivity. One of these 3 patients had probable immune-mediated hypersensitivity, whereas the remaining 2 had probable Cox-1-mediated reactions. The regimen of desensitization we employed for each patient was designed to account for the probable mechanism of hypersensitivity in the individual and further modified according to the degree of tolerance observed, with all 3 patients eventually achieving a daily cardioprotective dosage of ASA.

Original languageEnglish (US)
Pages (from-to)170-173
Number of pages4
JournalWorld Allergy Organization Journal
Volume5
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Vietnam
Aspirin
Coronary Artery Disease
Hypersensitivity
Drug Hypersensitivity
Immediate Hypersensitivity
Immunoglobulin E
Anti-Inflammatory Agents
Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

@article{afe38940d9d7437d9ee463a1c263772d,
title = "Description of 3 cases in Vietnam of aspirin desensitization in patients with coronary artery disease and coexisting aspirin hypersensitivity",
abstract = "Aspirin (ASA) hypersensitivity comprises types I to III (Cox-1 mediated) and types IV and V (IgE antibody mediated). Rapid, low-dose (81-325 mg/day) ASA desensitization regimens are known to be useful in establishing ASA tolerance in patients with coronary artery disease and coexisting ASA/nonsteroidal anti-inflammatory drug hypersensitivity. We document 3 cases in Vietnam of desensitization to ASA in patients with coronary artery disease and coexisting ASA hypersensitivity. One of these 3 patients had probable immune-mediated hypersensitivity, whereas the remaining 2 had probable Cox-1-mediated reactions. The regimen of desensitization we employed for each patient was designed to account for the probable mechanism of hypersensitivity in the individual and further modified according to the degree of tolerance observed, with all 3 patients eventually achieving a daily cardioprotective dosage of ASA.",
author = "{Van Nguyen}, Dinh and Chi, {Hieu Chu} and {Van Nguyen}, Doan and Craig, {Timothy J.} and {Van Nunen}, Sheryl",
year = "2012",
month = "11",
doi = "10.1097/WOX.0b013e3182718327",
language = "English (US)",
volume = "5",
pages = "170--173",
journal = "World Allergy Organization Journal",
issn = "1939-4551",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

Description of 3 cases in Vietnam of aspirin desensitization in patients with coronary artery disease and coexisting aspirin hypersensitivity. / Van Nguyen, Dinh; Chi, Hieu Chu; Van Nguyen, Doan; Craig, Timothy J.; Van Nunen, Sheryl.

In: World Allergy Organization Journal, Vol. 5, No. 11, 11.2012, p. 170-173.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Description of 3 cases in Vietnam of aspirin desensitization in patients with coronary artery disease and coexisting aspirin hypersensitivity

AU - Van Nguyen, Dinh

AU - Chi, Hieu Chu

AU - Van Nguyen, Doan

AU - Craig, Timothy J.

AU - Van Nunen, Sheryl

PY - 2012/11

Y1 - 2012/11

N2 - Aspirin (ASA) hypersensitivity comprises types I to III (Cox-1 mediated) and types IV and V (IgE antibody mediated). Rapid, low-dose (81-325 mg/day) ASA desensitization regimens are known to be useful in establishing ASA tolerance in patients with coronary artery disease and coexisting ASA/nonsteroidal anti-inflammatory drug hypersensitivity. We document 3 cases in Vietnam of desensitization to ASA in patients with coronary artery disease and coexisting ASA hypersensitivity. One of these 3 patients had probable immune-mediated hypersensitivity, whereas the remaining 2 had probable Cox-1-mediated reactions. The regimen of desensitization we employed for each patient was designed to account for the probable mechanism of hypersensitivity in the individual and further modified according to the degree of tolerance observed, with all 3 patients eventually achieving a daily cardioprotective dosage of ASA.

AB - Aspirin (ASA) hypersensitivity comprises types I to III (Cox-1 mediated) and types IV and V (IgE antibody mediated). Rapid, low-dose (81-325 mg/day) ASA desensitization regimens are known to be useful in establishing ASA tolerance in patients with coronary artery disease and coexisting ASA/nonsteroidal anti-inflammatory drug hypersensitivity. We document 3 cases in Vietnam of desensitization to ASA in patients with coronary artery disease and coexisting ASA hypersensitivity. One of these 3 patients had probable immune-mediated hypersensitivity, whereas the remaining 2 had probable Cox-1-mediated reactions. The regimen of desensitization we employed for each patient was designed to account for the probable mechanism of hypersensitivity in the individual and further modified according to the degree of tolerance observed, with all 3 patients eventually achieving a daily cardioprotective dosage of ASA.

UR - http://www.scopus.com/inward/record.url?scp=84872236665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872236665&partnerID=8YFLogxK

U2 - 10.1097/WOX.0b013e3182718327

DO - 10.1097/WOX.0b013e3182718327

M3 - Article

C2 - 23282385

AN - SCOPUS:84872236665

VL - 5

SP - 170

EP - 173

JO - World Allergy Organization Journal

JF - World Allergy Organization Journal

SN - 1939-4551

IS - 11

ER -